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Abstract
Analysis of routine population-based data has previously shown that patterns of sur-
gical treatment for colorectal cancer can vary widely, but there is limited evidence
available to determine if such variation is also seen in the use of chemotherapy. This
study quantified variation in adjuvant chemotherapy across both England using can-
cer registry data and in more detail across the representative Yorkshire and Humber
regions. Individuals with Stages II and III colorectal cancer who underwent major
resection from 2014 to 2015 were identified. Rates of chemotherapy were calculated
from the Systemic Anticancer Treatment database using multilevel logistic regression.
Additionally, questionnaires addressing different clinical scenarios were sent to
regional oncologists to investigate the treatment preferences of clinicians. The
national adjusted chemotherapy treatment rate ranged from 2% to 46% (Stage II can-
cers), 19% to 81% (Stage III cancers), 24% to 75% (patients aged <70 years) and 5%
to 46% (patients aged ≥70 years). Regionally, the rates of treatment and the propor-
tions of treated patients receiving combination chemotherapy varied by stage (Stage
II 4%-26% and 0%-55%, Stage III 48%-71% and 40%-84%) and by age (<70 years
35%-68% and 49%-91%; ≥70 years 15%-39% and 6%-75%). Questionnaire
responses showed significant variations in opinions for high-risk Stage II patients with
both deficient and proficient mismatch repair tumours and Stage IIIB patients aged
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≥70 years. Following a review of the evidence, open discussion in our region has
enabled a consensus agreement on an algorithm for colorectal cancer that is intended
to reduce variation in practice.
K E YWORD S
adjuvant chemotherapy, colorectal cancer, multidisciplinary team, population-based, treatment
guidelines
1 | INTRODUCTION
The Food and Drug Administration approved the use of adjuvant fluo-
rouracil (5FU) chemotherapy for Stage III colon cancer in 1990; the
initial recommended duration of 1 year was revised down to 6 months
by the end of the decade.1,2 Since 2000, the uses of capecitabine and
oxaliplatin have been established, the former being shown to be at
least equivalent to 5FU and the latter further improving survival.3-6 In
2011, the National Institute for Health and Care Excellence (NICE)
released permissive guidance for the use of adjuvant chemotherapy
for high-risk Stage II disease. This was subsequently echoed in Ameri-
can Society of Clinical Oncology (ASCO) guidance and then incorpo-
rated into both National Comprehensive Cancer Network (NCCN) and
European Society for Medical Oncology (ESMO) guidance.7-9 More
recently the duration of treatment has been further shortened to
3 months; the evidence strongest when using oxaliplatin and
capecitabine (CAPOX) but the shorter course can still be considered
for single agent capecitabine or oxaliplatin and 5FU (FOLFOX).10,11
Again, ASCO and NCCN guidelines quickly adopted these changes as
a new standard of care for all except patients with high-risk Stage III
disease where 6 months is still recommended. More recently NICE
have recommended 3 months for all patients when using CAPOX.12
Beyond stage, benefits of adjuvant chemotherapy may differ by
molecular phenotype, patient age and site of disease. Microsatelite
instability is present in 15% of colorectal cancers and is a result of
deficient mismatch repair (dMMR) caused by a germline mutation in
an MMR gene or epigenetic inactivation of the MLH1 gene.13
Although dMMR is a good prognostic factor, especially in Stage II
disease, data on whether it is predictive treatment efficacy are
mixed.14,15
In terms of increasing age, data are mixed for single-agent fluo-
ropyrimidine; the QUASAR trial suggested diminishing benefit
whereas a pooled analysis of the ACCENT database showed benefit
was preserved in patients over 70 years.16,17 Data on oxaliplatin are
more consistent with no benefit found for patients over 70 years.18,19
Age-related variance in benefit may relate to both an ability to toler-
ate chemotherapy and differences in biology of disease with increas-
ing age.20
The evidence for a benefit of adjuvant chemotherapy for rectal
cancer patients is inconclusive. Following a review of the evidence,
ESMO concluded that the benefit of adjuvant 5FU following surgery
alone was smaller than for colon cancer. Randomized trials have not
shown benefit for adjuvant 5FU for patients who have received
neoadjuvant radiotherapy and no consistent survival benefit has been
shown for the addition of oxaliplatin to 5FU either during
chemoradiotherapy and/or in the adjuvant setting.21-25 Two studies
exploring total neoadjuvant treatment recently reported improved
3-year disease-free survival or disease-related treatment failure, but
data are too early to assess impact on survival.26,27
International bodies have provided guidance in these areas. The
NCCN and ESMO guidelines support testing and recommend obser-
vation alone for dMMR high-risk pT3 stage II disease.8 NICE and
ASCO do not include guidance based on MMR status. In terms of rec-
tal cancer, ESMO recommends that decision making should be shared
with the patient while balancing the risk of relapse and predicted tox-
icity. NCCN, NICE and ASCO are more definite and support the use
of adjuvant chemotherapy for both patients with higher risk disease
irrespective of pre-op treatment. Only NICE mentions patient age as a
factor to be considered in addition to performance status, comorbidity
and personal preferences.
Given the degree of variance in published guidelines, and lack of
a definitive evidence base for certain patient populations, there is
potential for variation in adjuvant chemotherapy decision making.
Colorectal cancer multidisciplinary Teams (MDTs) are responsible for
the treatment and management of patients in the English National
Health Service; ensuring every patient is discussed by a team of spe-
cialists including a clinical nurse specialist, surgeon, radiologist, oncol-
ogist, pathologist and gastroenterologist making sure all treatment
What's new?
Population-based data have shown that surgery practice for
colorectal cancer varies widely among different regions.
Here, the authors delved into the population data to quantify
the variation in adjuvant chemotherapy across England. They
found a surprisingly high variation in chemotherapy rates for
high-risk stage II patients, and they suggest this difference
results in part from clinicians' differing opinions about the
effectiveness of chemotherapy for these patients. By
highlighting the amount of regional variation in treatment
practice, they achieved a consensus agreement on an algo-
rithm they developed to provide standardized guidance for
the use of chemotherapy.
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options are considered. This study aimed to quantify any variation in
adjuvant chemotherapy treatment across England and to explore this
variation in greater detail using the large representative region of
Yorkshire. This evidence was then used to help develop a consensus
guideline for implementation across the region's 16 MDTs in an effort
to minimize variation and improve colorectal cancer outcomes.
2 | MATERIALS AND METHODS
2.1 | Study design
The study was designed as part of the Yorkshire Cancer Research Bowel
Cancer Improvement Programme (YCR BCIP); a regional intervention-
based programme that is aiming to significantly improve colorectal can-
cer outcomes across a large representative region (Yorkshire and the
Humber). It aims to do this by quantifying variation in practice and
engaging with regional MDTs to understand this and develop educa-
tional interventions. A number of specialty groups (surgery, clinical oncol-
ogy, medical oncology, radiology, pathology, clinical nurse specialists and
anaesthetics) have been established to provide clinical direction, review
the data and to develop appropriate initiatives. The YCR BCIP region
accounts for approximately 10% of the colorectal cancer population of
England28 and hosts 16 of the 146 nationwide colorectal MDTs.
The study employed an iterative design, involving the region's
oncologists on a number of occasions (Supplementary Figure S1). Var-
iation in the use of adjuvant chemotherapy was investigated at a
national level, using population-based data across all colorectal cancer
MDTs treating patients in England. A more detailed account of the
variation was then undertaken at a regional level, covering the MDTs
participating in the YCR BCIP. Simultaneously in a separate qualitative
study, the first of two rounds of questionnaires addressing the use of
adjuvant chemotherapy for CRC were sent to regional oncologists.
A series of face-to-face and teleconference meetings for all
oncologists from the YCR BCIP region were held to discuss the vari-
ance both in prescribing practice seen in regional and national data
and the approaches taken by different MDTs seen from the question-
naire responses. Subsequently a further round of questionnaires was
sent to assess if differences persisted and a further meeting to agree a
final treatment algorithm, for use across the 16 MDTs in the region,
with the aim to reduce treatment variation.
2.2 | Population-based data
Individuals aged ≥18 years, diagnosed with a first primary Stage II or
III colorectal cancer (International Classification of Diseases 10th revi-
sion: C18-C20) in England from 1 January 2014 to 31 December
2015, were provided by the National Cancer Registry and Analysis
Service. Through its data repository COloRECTal Repository
(CORECT-R), the UK Colorectal Cancer Intelligence Hub provides link-
age of these cancer registry data to a number of additional routine
data sets across the English National Health Service, including hospital
admission data and the systematic anticancer therapy (SACT) data
set.29 Submission of SACT data via electronic prescribing is mandatory
for all NHS-funded providers in England and includes all cancer
patients receiving systemic anticancer treatment. All patients who
underwent a major resection and had not received neoadjuvant radio-
therapy treatment were identified using previously described algo-
rithms.30,31 Patients were assigned a managing colorectal MDT using
the hospital admission procedure closest to the patient's diagnosis
date. If no procedure was found, the closest inpatient or outpatient
appointment to the diagnosis date at a hospital with a colorectal MDT
was used. The <1% of patients that could not be assigned an MDT
were excluded from the study. In addition, 3% of all patients in the
cancer registry data had an unknown stage of disease so it was not
possible to ascertain if any of these were Stage II or III cancer and will
have been excluded from these analyses. Two MDTs, including one
within the YCR BCIP region, were found to have not submitted SACT
data in the adjuvant setting at the time of data collection so were
excluded from the analysis.
Patients receiving chemotherapy treatment were identified in the
SACT data set if their first regimen after resection was within
6 months and the primary treatment diagnosis within SACT was con-
firmed as C18-C20. Those receiving the combination regimens of
CAPOX or FOLFOX and the single agent regimens of capecitabine or
5FU were classified as receiving adjuvant treatment. Patients receiv-
ing a regimen usually used for metastatic disease were assumed to
have progressed to an advanced disease stage and excluded (3% of
those receiving chemotherapy). Patients receiving nonstandard regi-
mens, commonly used for treatment of different cancers, were
assumed to have been coded incorrectly and excluded (<1% of those
receiving chemotherapy).
Multilevel logistic regression models were used to assess factors
associated with adjuvant chemotherapy treatment, treating MDT as a
random effect. The binary-dependent variable was set as whether the
patient received adjuvant chemotherapy or not. Analyses were strati-
fied by age and tumour stage, with the following covariates consid-
ered: age (when not stratified by), sex, socioeconomic status (income
domain of the Index of Multiple Deprivation 2010), Charlson comor-
bidity score32 and tumour stage (when not stratified by).
Funnel plots33 were used to compare the rates of adjuvant treat-
ment across MDTs within England. Each individual's probability of
adjuvant treatment was derived from the logistic model and used to
calculate MDT-specific treatment ratios. These were then multiplied
by the average national adjuvant treatment rate (indicated by the hori-
zontal line on the funnel plot) to calculate MDT-specific treatment
rates. These rates were then plotted against the MDT workload (num-
ber of major resections performed). The funnelcompar command in
Stata Version 15 was used to calculate and add 95% and 99.8% con-
trol limits around the average national rates, which is indicated by the
inner and outer dashed lines, respectively. Those MDTs falling outside
the range of limits are considered to be significantly different from
the national average at the P < .05 and P < .002 levels. Example of
Stata code for calculating and plotting MDT-specific treatment rates
is given in Supplementary Information.
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2.3 | Questionnaires
Two rounds of online surveys considering questions on the manage-
ment of adjuvant chemotherapy in the YCR BCIP region were sent to
all 14 medical and 15 clinical oncologists at the 16 regional MDTs to
complete. These were completed anonymously, but the oncologist's
MDT membership was reported. Questions related to general manage-
ment and a set of hypothetical patient scenarios relate to stage, MMR
status and age. In Round 1 of the questionnaires, patient scenarios
pertained to chemotherapy and radiotherapy naïve colorectal cancer
patients with Stage II (with and without high-risk features; T4 stage,
extramural vascular invasion, low nodal count, emergency surgery and
poor differentiation in pMMR patients) and Stage III disease (with either
IIIA or B stage). These were modified and repeated in Round 2 of the
questionnaires, along with another questionnaire specifically relating to
rectal cancer patients who had received neoadjuvant radiotherapy
treatment. For each set of patient scenarios, the oncologist was asked
to indicate their preferred treatment option. Recipients were given the
option to specify a different treatment option not listed in the set
treatment options. Question details and the treatment options available
are given in Supplementary Information.
3 | RESULTS
3.1 | Assessment of national variation
A total of 23 402 resected colorectal patients from England were
included in the analysis (52% Stage II and 45% Stage III). The number
of patients receiving adjuvant chemotherapy was 1872 (16%) and
6380 (56%) for Stage II and Stage III disease, respectively. The odds of
receiving treatment decreased with increasing age, comorbidity level
and socioeconomic deprivation and for those with a rectal cancer. The
choice of single agent or combination therapy varied greatly by age
and stage of disease (Table 1).
Across 144 English MDTs, the adjusted adjuvant chemotherapy
treatment rate ranged from 2% to 46% for Stage II patients (Figure 1A)











































































































































































F IGURE 1 Funnel plots for risk-adjusted adjuvant chemotherapy rates for colorectal cancer patients with Stage II tumours (A), Stage III
tumours (B), patients aged <70 years (C) and patients aged ≥70 years (D) by English MDTs for patients diagnosed from 1 January 2014 to
31 December 2015. Red points (A-Q) indicate MDTs covered by the Yorkshire Cancer Research Bowel Cancer Improvement Programme. The
solid line represents the average national rate, and the inner and outer dashed lines are the 95% and 99.8% control limits [Color figure can be
viewed at wileyonlinelibrary.com]
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by age, the treatment rate ranged from 24% to 75% for patients aged
<70 (Figure 1C) and from 5% to 46% for patients aged ≥70 (Figure 1D).
3.2 | Assessment of regional variation
The variation seen at national level was mirrored within the YCR BCIP
region (n = 2375), with overall rates of adjuvant treatment similar to
those outside the region (Supplementary Table S1).
Although a number of MDTs showed significantly outlying adjusted
rates for both Stage II and III diseases, this was most prominent for Stage
II (Figure 1). Variation was seen in the observed rates of patients receiv-
ing treatment (range: Stage II 4%-26%, Stage III 48%-71%). Combination
therapy was mostly higher for Stage III patients (range: 40%-84%) but
not for Stage II patients (range: 0%-55%) (Figure 2).
For patients aged <70 years, higher proportions of combination
therapy were observed (treatment range: 29-69%, combination range:
49-91%). For patients aged ≥70 years, MDTs had an overall observed
treatment rate of <40%, with a lower proportion of combination
therapy in all but two MDTs (treatment range: 14-38%, combination
range: 6-75%).
3.3 | Further investigation of regional variation
Responses to Round 1 (Stage II and III questionnaires) were received
from oncologists at 15 of the 16 regional MDTs. Responses to Round
2 (Stage II, Stage III and rectal cancer after neoadjuvant radiotherapy
questionnaires) were received from oncologists at 10, 10 and 13 of
the 16 MDTs, respectively. All but one regional MDT partook in at
least one of the questionnaires. MDT representation for each individ-
ual questionnaire can be found in Supplementary Table S2.
3.3.1 | MMR and DPD testing
All respondents cited informing adjuvant chemotherapy decision mak-
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F IGURE 2 Use of and type of adjuvant chemotherapy by MDTs (A-Q) in the Yorkshire Cancer Research Bowel Cancer Improvement
Programme for colorectal cancer patients with Stage II tumours (A), Stage III tumours (B), patients aged <70 years (C) and patients aged ≥70 years
(D), diagnosed from 1 January 2014 to 31 December 2015 [Color figure can be viewed at wileyonlinelibrary.com]
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sited screening for Lynch syndrome. In the second round of question-
naires, half of respondents reported that (dihydropyrimidine dehydro-
genase) DPD testing was available.
3.3.2 | Stage II disease
In Round 1 of the questionnaire (Figure 3), for patients displaying low-
risk features, the 15 oncologists were largely in agreement, with at
least 11 (73%) selecting surveillance at the treatment option for all
sets of patients <70 years. No oncologist reported chemotherapy as a
treatment option for those low-risk feature patients aged ≥70.
There was less agreement for patients displaying high-risk fea-
tures; for dMMR patients aged <70 years, clinicians were split
between the use of combination chemotherapy and observation; for
pMMR patients, clinicians were mostly split on whether they are sin-
gle agent or combination. With increasing age, clinician's decision
making became more conservative.
In Round 2 (Figure 3), T4 patient scenarios were separated out
from the high-risk patient group and the 13 oncologists were split on
single agent (n = 6, 46%) or combination (n = 6, 46%) for T4 pMMR
patients aged <70 years. Nearly all oncologists now favoured single
agent treatment for other high-risk pMMR patients in both those aged
<70 (n = 12, 92%) and those aged ≥70 (n = 13, 100%).
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Stage II: Round 2
Surveillance
Other
Single agent 6 months
OxCap 3 monthsF IGURE 3 Number of treatment
options selected by oncologists from
MDTs in the Yorkshire Cancer Research
Bowel Cancer Improvement Programme
to the set of Stage II patient scenarios. HR
− and HR+ indicate low- and high-risk
features; in Round 2 T4 disease is
separated from other high-risk features.
dMMR, deficient mismatch repair; pMMR,
proficient mismatch repair [Color figure
can be viewed at wileyonlinelibrary.com]
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3.3.3 | Stage III disease
In Round 1 of the questionnaire (Figure 4), for all Stage III patients
aged <70 years there was uniformity among the 15 oncologists for
recommending combination chemotherapy for pMMR patients, bar
one who recommended single agent treatment for those aged 60 to
69 years.
For Stage IIIA patients ≥70 years, the majority of oncologists
suggested single agent for pMMR patients (n = 9, 60%), but not for
dMMR patients (n = 3, 20%). For Stage IIIB patients ≥70 years, oncolo-
gists were split on single agent (n = 6, 40%), combination (n = 5, 33%)
and surveillance (n = 1, 7%) for pMMR patients; for dMMR patients,
more clinicians suggested combination chemotherapy (n = 9, 60%).
In Round 2 (Figure 4), oncologists generally displayed more agree-
ment but were still split on single agent (7/11, 64% in IIIA and 6/11,
55% in IIIB) or combination treatment (4/11, 36% in IIIA and 5/11,
45% in IIIB) for pMMR patients aged ≥70.
3.3.4 | Rectal cancer after neoadjuvant
radiotherapy
All 12 respondents indicated that their postoperative management of
patients treated with neoadjuvant radiotherapy differed from patients
with colon cancer. Eight (67%) oncologists reported that they used
both preoperative clinical and postoperative histological stage
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Stage III: Round 2
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F IGURE 4 Number of treatment
options selected by oncologists from
MDTs in the Yorkshire Cancer Research
Bowel Cancer Improvement Programme
to the set of Stage III patient scenarios.
dMMR, deficient mismatch repair; pMMR,
proficient mismatch repair [Color figure
can be viewed at wileyonlinelibrary.com]
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information, three (25%) reported that they used just only preopera-
tive cross-sectional imaging and one (8%) only postoperative histologi-
cal stage. Six (50%) oncologists reported they had a higher threshold
for using adjuvant chemotherapy for this group than for patients with
colon cancer and six also reported they did not consider single-agent
FU chemotherapy worthwhile for this patient group. Six (50%) oncolo-
gists reported they predominantly restrict adjuvant chemotherapy to
those under age 70. For patients with pathological complete response,
three (25%) reported that they would consider adjuvant chemother-
apy based on clinical stage at diagnosis.
3.4 | Treatment guideline
After the discussion among the region's oncologists at the consulta-
tion meetings in which the regional variation and previous published
evidence were discussed, a treatment algorithm for Stage II and III
colorectal patients was constructed and proposed as a guideline for
regional MDTs at various stages during the study, before the finalised
version was agreed upon (Figure 5). Given the ubiquitous availability
of MMR testing across the region, we included guidance for patients
with either dMMR or pMMR testing in accordance with ESMO and
F IGURE 5 Treatment guidelines
algorithm for colorectal cancer
patients agreed by oncologists in the
Yorkshire Cancer Research Bowel
Cancer Improvement Programme
[Color figure can be viewed at
wileyonlinelibrary.com]
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NCCN guidance. NICE is the only National body to mention age but
does not specify a cut point around which to pivot decision making.
We also did not include a specific age cut point. Sporadic dMMR
occurs more commonly in the elderly and the algorithm recommends
a more conservative approach in the absence of T4 or node positive
disease for this molecular type. For those with more advanced T or N
stage combination chemotherapy at full dose or observation is rec-
ommended on the understanding that comorbidity and performance
status will be taken into account in accordance with NICE guidance.
Hence, an older patient is less likely to be treated given the higher
rate of dMMR, comorbidity and frailty related lower performance sta-
tus. We limited treatment duration to 3 months when using OxCap
for all patients including those with higher risk-stage III disease in
accordance with NICE but discordant with NCCN and ASCO guid-
ance. The absolute difference in 3-year survival for these patients
treated for 3 and 6 months of OxCap in the IDEAL data set was 0.1%
against an increase in Grade 3 neurotoxicity of 6%. We provided guid-
ance on patients with rectal cancer who had received neoadjuvant
chemoradiotherapy, which was more conservative than NICE, ESMO,
NCCN and ASCO guidance and more akin to Dutch guidance.
4 | DISCUSSION
This study has demonstrated both national and regional variations in
the use of adjuvant chemotherapy treatment across MDTs managing
colorectal cancer in England. This variation was not explained by dif-
ferences in simple case mix factors at a national level nor more
detailed factors at a regional level. The study has highlighted a number
of inconsistencies in clinical practice across a large representative
region of England, specifically, on the use of adjuvant treatment for
Stage II high-risk dMMR patients, and the choice of single agent or
combination therapy for Stage II T4 pMMR patients and Stage III
pMMR patients aged ≥70. After consultation meetings with oncolo-
gists, a consensus treatment guideline has been developed.
Recently the benefits of chemotherapy over and above the presence
of modern multidisciplinary care in Stage II disease, and for some Stage
III disease patients, have been questioned.34 Given that it is not currently
possible to identify the high-risk stage II patients within the national reg-
istry data, some variation in treatment rates for these patients may have
been anticipated. The extent of this variation appears, however, to be
surprisingly high and so unlikely to be explained by differences in patient
and tumour characteristics but rather a result of clinician preference. This
view is supported by the results of the questionnaire with regard to
Stage II high-risk dMMR patients. Given the lack of evidence for
improved outcomes for low-risk dMMR patients,35 the algorithm devel-
oped here recommends adjuvant treatment over surveillance only for
those dMMR patients with the strongest adverse risk factor, T4 stage.
Poor differentiation is not a risk factor of dMMR tumours and the
improved outcomes seen with dMMR counter the adverse prognosis
attributed to the presence of vascular invasion. The evidence base guid-
ing which regimen to use for dMMR tumours is mixed, but provided con-
cerns that single-agent fluoropyrimidines are ineffective and combination
chemotherapy is recommended. If patients are not fit for such, then sur-
veillance is recommended.
For Stage III patients, some form of adjuvant treatment was
suggested by oncologists for most patients regardless of MMR status
or age. Hence, differences in opinion of oncologists do not explain sig-
nificant variation seen in adjusted rates across MDTs in the regional
and national data. There were differences in opinion for the choice of
single agent or combination chemotherapy for elderly Stage III
patients. The majority of clinicians recommended single-agent chemo-
therapy for Stage IIIA patients in keeping with evidence, suggesting
patients over 70 years do not benefit from the addition of oxaliplatin
but more clinicians recommended combination chemotherapy for
Stage IIIB patients. The algorithm does not specify age cut off but
focuses on fitness for full-dose chemotherapy and disease biology.
The reasons for the lack of benefit observed in patients over 70 years
are unclear but we recognize that sporadic dMMR is more frequently
observed in older patients and therefore may be a contributing factor.
This study has a number of limitations, which we were unable to
fully address. Although SACT data submission has been mandatory for
all NHS providers in England from 2014,36 it appears this is not fully
complied to for the period covered here, as two MDTs were found to
have no adjuvant chemotherapy-treated patients. Additionally, the can-
cer registry data do not provide full information on characteristics to
identify high-risk patients and other potentially important factors relat-
ing to treatment decisions such as comorbidities not recorded through
the Charlson comorbidity index. However, the additional data collection
in this study compensates somewhat for these omissions and empha-
sises the variation shown in national data sets. Patient choice is also
likely to be factor here, but it was not possible to account for this in the
data used in this study. Previous studies have demonstrated that an
increased travel burden is associated with a decreased likelihood of
receiving adjuvant chemotherapy.37,38 It was not possible to assess this
within our data, however, a systematic review in the United Kingdom
concluded that while variation between healthcare boundaries were
observed, other factors such as capacity and treatment policy were
more influential than geographical factors.39
The patient scenarios in the questionnaires used age as a patient
group. Although in some cases this may be a suitable proxy for frailty
and fitness to undergo chemotherapy treatment, discussions among
the regional oncologists made it clear that a more appropriate measure
would be ideal. The algorithm has used the relatively bland term “fit for
chemotherapy” based on the expectation that clinicians will factor a
patient's comorbidity, performance status and preference during deci-
sion making in keeping with NICE guidance. We recognize that ASCO
have released guidance on assessment of older patients receiving che-
motherapy.40 The tools highlighted in this guidance document have
been developed largely in patients with advanced disease and are not
tumour site specific.41-43 There is a need to develop a tool to help pre-
dict which patients are likely to tolerate and complete adjuvant chemo-
therapy for colorectal cancer. The linked datasets accessed through this
work provides an opportunity to further explore this area.
The algorithm developed here provides general guidance to adju-
vant treatment; however, it is not expected to provide a definite
10 TAYLOR ET AL.
stratification of patients as it is not possible to take in account all
patient characteristics at such a level. Care must be taken if extending
the algorithm for use in other populations, for instance, this study
used National Health Service data where access to treatment is good
and therefore it was not necessary to take into account factors such
as health insurance status and patient access.
In summary, this study has identified considerable variation in the
management of adjuvant chemotherapy for colorectal cancer at regional
and national levels. Bringing this information to the attention of clinicians
through the YCR BCIP enabled a consensus agreement on a proposed
algorithm to reduce treatment variation across a large representative
region of England. Such a process could be replicated in other regions.
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